68 Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study

• Published in: The Journal of nuclear medicine (1978)
• Main Authors: Kesler, Mikhail, Levine, Charles, Hershkovitz, Dov, Mishani, Eyal, Menachem, Yoram, Lerman, Hedva, Zohar, Yaniv, Shibolet, Oren, Even-Sapir, Einat
• Format: Journal Article
• Language: English
• Published: United States 12.07.2018
• Subjects: PSMA; Oncology: Liver; Hepatology; PET/CT; FDG; Hepatocellular carcinoma; PET
• ISSN: 1535-5667

Ga-Prostate Specific Membrane Antigen ( Ga-PSMA), a positron emission tomography (PET) tracer that was recently introduce for imaging of prostate cancer, may accumulate in other solid tumors including Hepatocellular Carcinoma (HCC). The aim of the study was to assess the potential role of Ga-PSMA PET-Computed Tomography (CT) for imaging of HCC. A prospective pilot study in seven patients with HCC with 41 liver lesions: 37 suspected malignant lesions (tumor lesions) and 4 regenerative nodules. For each liver lesion, uptake of Ga-PSMA and F-FDG uptake were measured [standard uptake value (SUV) and lesion-to-liver background ratios (TBR-SUV)], and correlated with dynamic characteristics (HU and TBR-HU) obtained on contrast enhanced CT data. Immunohistochemistry staining of PSMA in the tumor tissue was analyzed in samples obtained from 5 patients with HCC and compared to control samples from 3 patients with prostate cancer. Thirty-six of the 37 tumor lesions and none of the regenerative nodules showed increased Ga-PSMA uptake while only 10 lesions were F-FDG avid. Based on contrast enhancement, tumor lesions were categorized into 27 homogeneously enhancing lesions, nine lesions with "mosaic" enhancement composed of enhancing and non-enhancing regions in the same lesion and a single non-enhancing lesion, the latter being the only non- Ga-PSMA avid lesion. Using the Mann-Whitney test, Ga-PSMA uptake was found significantly higher in enhancing tumor areas compared to non-enhancing areas and in contrast, F-FDG uptake was higher in non-enhancing areas, P<0.001 for both. Ga-PSMA uptake (TBR SUV ) was found to correlate with vascularity (TBR-HU) (Spearman r=0.866, p<0.001). Immunohistochemistry showed intense intra-tumoral microvessel staining for PSMA in HCC, in contrast with cytoplasmic and membranous staining, mainly in the luminal border, in prostate cancer samples. In two of the study patients Ga-PSMA PET-CT identified unexpected extrahepatic metastases. Four regenerative liver nodules showed no increased uptake of either of the PET tracers. Ga-PSMA PET-CT is superior to F-FDG PET-CT in imaging patients with HCC. HCC lesions are more commonly hypervascular taking up Ga-PSMA in tumoral micro-vessels. Ga-PSMA PET-CT is a potential novel modality for imaging patients with HCC.